BioCryst Q1 ORLADEYO revenue $88.9M (+30% YoY); 2024 guidance raised to $390-$400M

BIOCRYST PHARMACEUTICALS INC

2024-Q1 EPS reported -$0.17 revenue$92,761,000

Q1 net loss narrowed to $35.4M ($0.17/sh) from $53.3M ($0.28/sh) a year ago.
ORLADEYO net revenue grew 30% YoY to $88.9M; full-year guidance raised to $390-$400M (top end of prior range).
Pipeline: BCX17725 (Netherton syndrome) enters clinic by end 2024; avoralstat (DME) trial planned for 2025.
Pediatric HAE trial (APeX-P) enrollment complete; filing for label expansion to children age 2+ expected in 2025.
Cash and investments $338.4M at Mar 31; net cash use Q1 $52.4M, expects ending 2024 cash above $300M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOCRYST PHARMACEUTICALS INC reported the first quarter ended March 31, 2024 results: revenue $92.8 million, net income $35.4 million, EPS $0.17 per share. Guidance raised.

Period: the first quarter ended March 31, 2024
Revenue: $92.8 million
Net income: $35.4 million
EPS: $0.17 per share
Guidance: raised
Result: reported results

Exact text from the filing

said Dr. Helen Thackray, chief research and development officer of BioCryst. First Quarter 2024 Financial Results For the three months ended March 31, 2024, total revenues were $92.8 million, compared to $68.8 million in the first quarter of 2023 (+34.9 percent y-o-y). The increase was primarily due to $88.9 million in ORLADEYO net revenue in the first quarter of

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-24-002550

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.